linjc16/ctgov huggingface dataset:
Subcutaneous Injection of Erythropoietin on Visual Functions in Patients With Late Onset Optic Neuropathy

Study Overview
=================
Brief Summary
-----------------
This study aimed to investigate the therapeutic effect of subcutaneous erythropoietin in the management of late stage optic neuropathy.

Detailed Description
-----------------
Injury of the optic nerve or optic neuropathy is one of the most common causes of vision loss. This study aimed to investigate the therapeutic effect of subcutaneous erythropoietin in the management of late stage optic neuropathy.

Official Title
-----------------
Evaluation of the Effect of Subcutaneous Injection of Erythropoietin on Visual Functions in Patients With Late Onset Optic Neuropathy

Conditions
-----------------
Optic Neuropathy

Intervention / Treatment
-----------------
* Drug: erythropoietin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with late stage optic neuropathy (1 month to 12 months after onset of optic neuropathy due to late referral of the cases) Exclusion Criteria: Patients with perforating ocular injuries were excluded.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Interventional Model Description: The study included 20 patients diagnosed as late onset optic neuropathy that are attending Alexandria main university hospital. All patients underwent initially assessment of visual acuity, color vision, pupil reaction ,funduscopy and electrophysiological tests ( pattern visual evoked potential and pattern electroretinogram in both eyes to use data of the normal fellow eye as patients' internal control). Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days). Follow up after one month and three months by recording visual acuity and electro physiological studies.
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Systemic erythropoietin injections<br>20 patients diagnosed as late onset optic neuropathy that were attending Alexandria main university hospital.Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days). | Drug: erythropoietin<br>* Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of visual acuity | Visual acuity using appropriate charts for assessment then convert into log of the minimum angle of resolution (logMAR) units to provide a numeric scale of visual acuity | 3 months | 
| Flash visual-evoked potentials | Flash VEP to detect amplitude reduction and latency in the optic nerve. | 3 months |
Use of Metal Stents on Benign Esophageal Lesions

Study Overview
=================
Brief Summary
-----------------
The evaluation of using metal stents as medically indicated for the treatment of benign esophageal lesions.

Official Title
-----------------
Prospective Evaluation of the Clinical Utility of the Endoscopic Placement of Mental Stent for Benign Esophageal Lesions

Conditions
-----------------
Benign Esophageal Lesions

Intervention / Treatment
-----------------
* Procedure: Endoscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject is 18 years or older Subject has medical indication to undergo endoscopic placement of esophageal metal stent Subject must be able to give informed consent Exclusion Criteria: Any contraindications for endoscopic placement of esophageal metal stent The subject is unable to give informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| benign esophageal lesions<br>All patients who have a benign esophageal lesion where it is medically indicated that they receive a stent. | Procedure: Endoscopy<br>* Endoscopic placement of an esophageal metal stent as per medical indication.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Successful stenting of Benign esophageal lesions | This is an observational study to determine the effectiveness of stenting benign esophageal lesions with a metal stent. | approximately 2-3 hours |
Evaluation of Adherence to Solifenacin Treatment in Overactive Bladder Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to assess patient's persistency in maintaining solifenacin treatment for overactive bladder.

Official Title
-----------------
Persistence of Solifenacin Treatment in Overactive Bladder Patients in Real Life Practice: A 12-month, Prospective, Multicenter, Open-label, Observational Study

Conditions
-----------------
Urinary Bladder, Overactive, Overactive Bladder

Intervention / Treatment
-----------------
* Drug: Solifenacin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Overactive bladder symptoms lasting for more than 3 months The question 3 score of the overactive bladder symptom score(OABSS)≥ 2 and the sum score of OABSS ≥ 3 Symptoms of urinary urgency defined as a level of 1 to 2 in a 3-point Urgency Perception Scale (UPS) Exclusion Criteria: Any condition that would contraindicate their usage of anticholinergic treatment, including: urinary retention, gastric retention, uncontrolled narrow angle glaucoma, myasthenia gravis Symptomatic acute urinary tract infection (UTI) Diagnosed or suspected of interstitial cystitis Treatment with anticholinergic drugs for over 3 months within 12 months prior to the study Pregnant or nursing women Treatment within the 14 days before the study or expected to initiate treatment during the study with any anticholinergic drugs other than solifenacin or treatment for overactive bladder with other drugs Any other condition which, in the opinion of the investigator, makes the patient unsuitable for inclusion

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Solifenacin treatment<br>Male and female OAB patients who were treated with solifenacin | Drug: Solifenacin<br>* oral<br>* Other names: Vesicare;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| percentage of patients who are maintaining solifenacin treatment |  | Month 0, Month 1, Month 3, Month 6, Month 9 and Month 12 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| percentage of patients who discontinued solifenacin treatment |  | Month 0, Month 1, Month 3, Month 6, Month 9 and Month 12 | 
| percentage of patients who switched to other OAB medication |  | Month 0, Month 1, Month 3, Month 6, Month 9 and Month 12 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Solifenacin, Overactive bladder, persistency of the treatment, Vesicare
Otologic and Rhinologic Outcomes in Children With Clef Palate

Study Overview
=================
Brief Summary
-----------------
OBJECTIVE: To compare otologic and rhinologic outcomes in patients with cleft palate according to surgical protocols and type of cleft. DESIGN: Monocentric retrospective and prospective analysis of medical reports. PATIENTS, PARTICIPANTS: All consecutively treated patients affected by a cleft palate, born between December 2006 and December 2009 and followed in the Montpellier University Hospital, at the age of 10 years. INTERVENTIONS: Results of audiometry, tympanometry, otoscopy, tubomanometry and rhinomanometry and orofacial tomodensitometry done at the age of 10 were evaluated. MAIN OUTCOME MEASURE(S): The history of ventilation tubes inserted, and the results at the EDTQ test were analyzed.

Official Title
-----------------
Otologic and Rhinologic Outcomes in Children With Cleft Palate at Age 10 Years

Conditions
-----------------
Cleft Lip and Palate

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria : 10 yo children with operated clefts followed in the universitary hospital of Montpellier who went to the ENT check up Exclusion criteria : Thoses who skip the check up

Ages Eligible for Study
-----------------
Minimum Age: 9 Years
Maximum Age: 11 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Children with Cleft lip and palate<br>Children with Cleft lip and palate | |
| Children with Cleft palate<br>Children with Cleft palate | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Audiometry | evaluation of the hearing threshold | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| nasal ventilation | Nasal ventilation will be assessed with passive anterior rhinomanometry | 1 day | 
| Eustachian tube function | Eustachian tube function will be assessed with tubomanometry | 1 day | 
| Facial 3D scan | Facial 3D scan will be used to measure 2 criteria : Total volum of the mastoid Total volum of the mastoid's cells (pneumatization) Facial 3D scan will be used to measure 2 criteria : Total volum of the mastoid Total volum of the mastoid's cells (pneumatization) Facial 3D scan will be used to measure 2 criteria : Total volum of the mastoid Total volum of the mastoid's cells (pneumatization) | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cleft palate, Eustachian dysfunction, Obstructive ventilation
A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)

Study Overview
=================
Brief Summary
-----------------
The clinical study determines the safety and efficacy of Sitagliptin (MK0431) in patients with type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy.

Official Title
-----------------
Sitagliptin (MK0431) Phase III Double-blind Comparative Study - Type 2 Diabetes Mellitus -

Conditions
-----------------
Diabetes Mellitus, Non-Insulin-Dependent

Intervention / Treatment
-----------------
* Drug: sitagliptin phosphate
* Drug: Comparator: voglibose


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients have type 2 diabetes mellitus on diet/exercise therapy Exclusion Criteria: Patients have type 1 diabetes mellitus

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Sitagliptin 50 mg QD<br>sitagliptin 50 mg orally once daily (QD=once daily) | Drug: sitagliptin phosphate<br>* sitagliptin 50 mg orally once daily QD. Duration of Treatment: 12 Weeks<br>* Other names: MK0431;|
| Active Comparator: Voglibose 0.2 mg TID<br>voglibose 0.2 mg orally three times daily (TID= three times daily) | Drug: Comparator: voglibose<br>* voglibose 0.2 mg orally three times daily TID. Duration of Treatment: 12 Weeks<br>* Other names: voglibose;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change From Baseline in HbA1c at Week 12 | HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 12 HbA1c percent minus the Week 0 HbA1c percent. | Baseline and Week 12 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change From Baseline in Fasting Plasma Glucose at Week 12 | Change from baseline at Week 12 is defined as fasting plasma glucose at Week 12 minus fasting plasma glucose at Week 0. | Baseline and Week 12 | 
| Change From Baseline in 2 Hour Postprandial Glucose at Week 12 | Change from baseline at Week 12 is defined as 2-hour postprandial glucose Week 12 minus 2-hour postprandial glucose Week 0. | Baseline and Week 12 |
Clinical Utility of the Spyglass System in Primary Sclerosing Cholangitis (PSC)

Study Overview
=================
Brief Summary
-----------------
This study aim to prospectively evaluate the clinical utility of Spyglass in sclerosing cholangitis patients undergoing endoscopic retrograde cholangiopancreaticography (ERCP). Fifty patients with a definite diagnosis of sclerosing cholangitis and a clinical indication for ERCP from September 2008 and onwards will be investigated with peroral cholangioscopy using Spyglass direct visualization system. Clinical data on all patients will be collected at time of the ERCP including information on the Primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD), serum liver function tests and indication for ERCP. A structured data collection form including information on Majoie Score, macroscopic features of the bile ducts at cholangioscopy, quality of the investigation, technical difficulties, and an overall judgment of whether any abnormalities observed were benign or malignant was completed by the endoscopist in conjunction with the procedure.

Official Title
-----------------
Prospective Evaluation of the Clinical Utility of Peroral Cholangiopancreatoscopy With the Spyglass System in Patients With Sclerosing Cholangitis

Conditions
-----------------
Sclerosing Cholangitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: sclerosing cholangitis with indication for ERCP Over 18 year informed consent Exclusion Criteria: Not able to sign informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Primary sclerosing cholangitis<br>Patients with a definite diagnosis of sclerosing cholangitis and a clinical indication for ERCP. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Endoscopic retrograde cholangiopancreaticography, Sclerosing cholangitis, Spyglass
Genetic Study in Patients With Stage II or Stage III Colon Cancer

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Genetic studies may help in understanding the genetic processes that cause some types of cancer. PURPOSE: Genetic trial to study certain genes of patients who have stage II or stage III colon cancer.

Detailed Description
-----------------
OBJECTIVES: Determine the adverse prognostic significance of 8p allelic imbalance (AI) in patients with colon cancer. Determine if patient prognosis is dependent on the region of 8p AI. Perform fine mapping studies to further localize the putative tumor suppressor gene(s) on 8p. Perform multicolor FISH to examine the role that 8p loss and 8q gain play in the prognosis of patients whose tumors exhibit 8p AI. OUTLINE: Matched normal and tumor DNA is analyzed for 8p allelic imbalance with at least 8 markers: D8S262 and D8S1825 localized to 8p23, D8S254 and D8S261 at 8p22, D8S560 and D8S136 at 8p21, and D8S1820 and D8S283 at 8p12. Normal/tumor tissue pairs are used for fine mapping studies.

Official Title
-----------------
The Clinical and Pathological Significance of Allelic Imbalance of 8p in Patients With Colorectal Cancer

Conditions
-----------------
Colorectal Cancer

Intervention / Treatment
-----------------
* Genetic: DNA stability analysis
* Genetic: gene mapping


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Diagnosis of resectable stage II or III adenocarcinoma of the colon Participated in NCCTG-914653 DNA extracted from both normal and tumor tissue PATIENT CHARACTERISTICS: Age Under 70

Ages Eligible for Study
-----------------
Maximum Age: 69 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Normal and tumor tissue pairs<br>Matched normal and tumor DNA is analyzed for 8p allelic imbalance with at least 8 markers: D8S262 and D8S1825 localized to 8p23, D8S254 and D8S261 at 8p22, D8S560 and D8S136 at 8p21, and D8S1820 and D8S283 at 8p12. Normal/tumor tissue pairs are used for fine mapping studies. | Genetic: DNA stability analysis<br> <br> Genetic: gene mapping<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| overall survival |  | Up to 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
stage II colon cancer, stage III colon cancer, adenocarcinoma of the colon
Retrospective Analysis for Patients With Hemophagocytosis in Bone Marrow

Study Overview
=================
Brief Summary
-----------------
Comparison of malignant and non-malignant disorders associated bone marrow hemophagocytosis.

Detailed Description
-----------------
This is a retrospective study comparing malignant and non-malignant disorders associated bone marrow hemophagocytosis. The medical record of patients who had documented evidences of hemophagocytosis in bone marrow are reviewed. The clinical and biological characteristics are compared according to the underlying disorders of hemophagocytosis.

Official Title
-----------------
Comparison of Malignant and Non-malignant Disorders Associated Bone Marrow Hemophagocytosis: A Single Center Experience

Conditions
-----------------
Hemophagocytosis

Intervention / Treatment
-----------------
* Other: Hemophagocytosis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients who had evidence of hemophagocytic histiocytosis in bone marrow aspiration and biopsy Exclusion Criteria: patients who did not evidence of hemophagocytic histiocytosis in bone marrow aspiration and biopsy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Hemophagocytosis<br>The group includes patients who have the evidence of hemophagocytosis in their bone marrow or other sites. | Other: Hemophagocytosis<br>* Best supportive care and immunosuppressive treatments<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival |  | 12 Months |
SARS Cov_2 Incidence of Healthy Health Workers

Study Overview
=================
Brief Summary
-----------------
Since the severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) first emerged in Wuhan, China, on 12 December 2019, it has spread rapidly across the world and developed into a pandemic. The pandemic has affected over 100 countries and regions, with over 132 million confirmed cases of COVID-19. The rapid spread of SARS-CoV-2 has caused considerable harm to public health and the economy. Alongside other laboratory tests and clinical findings of the COVID-19 infection, serological testing may be beneficial for epidemiological monitoring and outbreak control. The determination of antibodies enables confirmation of the SARS-CoV-2 infection in asymptomatic patients in addition to those with typical symptoms. In this study, we aimed to determine the SARS-CoV-2 seroprevalence and the IgG antibody levels among healthcare workers who frequently encountered COVID-19 patients in our hospital.

Official Title
-----------------
Evaluation of IgG Neutralizing Antibodies to SARS-CoV-2 Among Healthcare Workers Who Frequently Encountered COVID-19 Patients in Our Hospital

Conditions
-----------------
SARS COV-2 IgG Levels on Health Workers

Intervention / Treatment
-----------------
* Diagnostic Test: Spike protein (S) or the nucleocapsid (N) of SARS-CoV-2


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy Health Workers - SARS COV-2 PCR (-) Exclusion Criteria: Health Workers - SARS COV-2 PCR (+) Pregnancy Autoimmune diseases Received immunosuppressive therapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: SARS Cov_2 Incidence of Healthy Health Workers<br> | Diagnostic Test: Spike protein (S) or the nucleocapsid (N) of SARS-CoV-2<br>* Blood level of spike protein (S) or the nucleocapsid (N) of SARS-CoV-2<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of IgG Neutralizing Antibodies to SARS-CoV-2 Among Healthcare Workers Who Frequently Encountered COVID-19 patients in Our Hospital | Determining antibody levels and seroprevalence of healthy healthcare workers | 6 months |